RaQualia Pharma Inc. (TYO:4579)

Market Cap	26.09B +207.9%
Revenue (ttm)	3.05B +9.9%
Net Income	-724.12M
EPS	-31.50
Shares Out	26.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	272,600
Average Volume	985,635
Open	1,000.00
Previous Close	1,000.00
Day's Range	996.00 - 1,013.00
52-Week Range	301.00 - 1,465.00
Beta	0.84
RSI	46.69
Earnings Date	Feb 13, 2026

About RaQualia Pharma

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. The company human products portfolio includes tegoprazan for gastroesophageal reflux disease; and grapiprant for cancer and pain management; RQ-00000008 for the treatment of osteoarthritis autoimmune disorders; RQ-00000010 to treat gastroparesis. It also provides veterinary products, such as capromorelin to treat anorexia in dogs and weight management in cats; grapiprant for osteoarthritis in dogs; RQ-00000008 to treat osteoarthritis and others; ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 64
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4579

Financial Performance

In 2024, RaQualia Pharma's revenue was 3.11 billion, an increase of 63.44% compared to the previous year's 1.90 billion. Losses were -495.00 million, 53.3% more than in 2023.